drugset / Trial / NCT06769425
HS-10502 Combination Treatment in Patients With Advanced Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
HS-10502 is a PARP1-specific selective inhibitor. The purpose if this study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10502 Combination Treatment in subjects with advanced solid tumors.
Timeline
- Start
- 2025-05-07
- Primary completion
- 2026-05-07
- Completion
- 2026-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | — |
| Subject | Docetaxel | Small molecule | — | — |
| Subject | HS-10502 | Unknown | — | Oral |
| Subject | HS-20089 | Monoclonal antibody | — | — |
| Subject | HS-20093 | Other / unclassified | — | — |
| Subject | Irinotecan | Small molecule | — | — |
| Subject | Paclitaxel | Small molecule | — | — |
| Subject | Rivoceranib | Small molecule | — | — |